BAGANBAZAR GRAPHEXPLORE · ANALYZE · GROW
Theme
LiveDesk
WorldKnight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in BrazilWorldTaylor Swift lands top trophy at MTV’s Video Music AwardsWorldTrump says men arrested at UK air base used by US were looking to do ‘big damage’WorldThe Snoop: Gillard appears at UK Labour conference, Australian exodus from Saudi Arabia, and moreWorldThe US could send Australian personal data to third countries under secret ‘partnership’
World/Source-attributed reporting
World DESK

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and […]

Published Aug 28, 2026 · 2:30 AMOriginal source: Financial Post3 reads
MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and […]
ORIGINAL SOURCE

Financial Post

This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.

Read at original outlet ↗
RELATED COVERAGE

More from this desk.